Expiration date: 06/2026

ATX
L01XX05 Hydroxycarbamide
Pharmacological group: Antimetabolites
Nosological classification (ICD-10)
    C15-C26 malignant neoplasms of digestive organs
    C30-C39 Malignant neoplasms of respiratory organs and chest
    C50 malignant neoplasms of breast
    C56 Malignant neoplasm of ovary
    C58 malignant neoplasm of placenta
    C92 Myeloid leukemia [myeloid leukemia]
    C95 leukemia, unspecified cell type
Composition and form of issue
1 capsule contains hydroxycarbamide 500 mg, in a glass bottle 100 PCs., in a box 1 bottle.
Pharmacological action
The drugs - antitumoral
Inhibits the synthesis of DNA.
Pharmacokinetics
Cmax is achieved in 2 hours after administration. Quickly penetrates into the tissues, in the cerebrospinal fluid is 10-20%, in ascitic-15-50% concentration in plasma. After 24 hours, the serum content is approaching zero. T1/2 — 3-4 h with 80% excreted by kidneys within 12 h
The testimony of the drug Hydrea™
Chronic and acute myeloid leukemia, blast crises in chronic myeloid leukemia, melanoma, breast and stomach carcinoma, tumors of the head and neck (if it is impossible or possible only partially resection or irradiation), ovarian cancer, uterine choriocarcinoma, acute lymphoblastic leukemia in children (relapses), lung cancer. It is also used in conjunction with radiation therapy (to improve its effectiveness) for cervical cancer and brain tumors.
Contraindications
Hypersensitivity, leukopenia (less than 3000/mm3), thrombocytopenia (less than 100000/mm3).
Use during pregnancy and breast-feeding
Contraindicated
Side effect
Reversible bone marrow hypoplasia, thrombocytopenia, nausea, vomiting, partial alopecia and spotty-papular skin reactions.
Interaction
Increases the effect of cytarabine, weakens to 5-fluorouracil and methotrexate. While taking antidepressants, antihistamines, barbiturates, sedatives, sleeping pills, drugs and alcohol increases the inhibition of the reaction rate.
Dosage and administration
Inside, before meals. Treatment is usually carried out by periodic courses. 80 mg/kg once every 3 days or daily 20-30 mg / kg once (doses are given based on actual or normal body weight, and the smaller of these values is used). In elderly patients, it is advisable to use lower doses. During treatment, patients should consume a sufficient amount of fluid.
Overdose
Treatment is symptomatic, because there is no specific antidote, is not subject to dialysis.
Storage conditions of Hydra™
In a place protected from light, at a temperature of 15-25 °C.